CA3241479A1 - Formulations topiques de ruxolitinib avec un agent d'ajustement du ph a base d'amine organique pour le traitement de maladies de la peau - Google Patents

Formulations topiques de ruxolitinib avec un agent d'ajustement du ph a base d'amine organique pour le traitement de maladies de la peau

Info

Publication number
CA3241479A1
CA3241479A1 CA3241479A CA3241479A CA3241479A1 CA 3241479 A1 CA3241479 A1 CA 3241479A1 CA 3241479 A CA3241479 A CA 3241479A CA 3241479 A CA3241479 A CA 3241479A CA 3241479 A1 CA3241479 A1 CA 3241479A1
Authority
CA
Canada
Prior art keywords
formulation
component
weight
water
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3241479A
Other languages
English (en)
Inventor
Naresh MODEPALLI
Trupti SHETH
Marc Brown
Charles Evans
James Fidge
Florencia GUIDALI
Tecashanell MCINTOSH
Vanessa COFRE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/541,601 external-priority patent/US12005067B2/en
Application filed by Incyte Corp filed Critical Incyte Corp
Priority claimed from PCT/US2022/080873 external-priority patent/WO2023102559A1/fr
Publication of CA3241479A1 publication Critical patent/CA3241479A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente divulgation concerne des formulations topiques et des méthodes de traitement de maladies de la peau faisant appel à des formulations topiques comprenant un inhibiteur de JAK 1/2, qui est le ruxolitinib, ou un sel pharmaceutiquement acceptable de celui-ci, et un agent d'ajustement du pH à base d'amine organique. Les maladies de la peau à traiter comprennent, entre autres, le psoriasis, la dermatite atopique, l'alopécie, le vitiligo, le syndrome de Reiter, le pityriasis rubra pilaire, l'épidermolyse bulleuse simple, la kératodermie palmoplantaire, la pachyonychie congénitale, le stéatocystome multiple, le lichen plan cutané, le lymphome cutané à cellules T, l'hidradénite suppurée, la dermatite de contact, l'ictère, et le trouble de la kératinisation. L'agent d'ajustement du pH à base d'amine organique est une amine tertiaire ou une alcanolamine.
CA3241479A 2021-12-03 2022-12-04 Formulations topiques de ruxolitinib avec un agent d'ajustement du ph a base d'amine organique pour le traitement de maladies de la peau Pending CA3241479A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17/541,601 2021-12-03
US17/541,601 US12005067B2 (en) 2020-12-04 2021-12-03 JAK inhibitor with a vitamin D analog for treatment of skin diseases
US202263365973P 2022-06-07 2022-06-07
US63/365,973 2022-06-07
PCT/US2022/080873 WO2023102559A1 (fr) 2021-12-03 2022-12-04 Formulations topiques de ruxolitinib avec un agent d'ajustement du ph à base d'amine organique pour le traitement de maladies de la peau

Publications (1)

Publication Number Publication Date
CA3241479A1 true CA3241479A1 (fr) 2023-06-08

Family

ID=88559166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3241479A Pending CA3241479A1 (fr) 2021-12-03 2022-12-04 Formulations topiques de ruxolitinib avec un agent d'ajustement du ph a base d'amine organique pour le traitement de maladies de la peau

Country Status (9)

Country Link
EP (1) EP4440546A1 (fr)
JP (1) JP2024544686A (fr)
KR (1) KR20240139048A (fr)
CN (1) CN118714997A (fr)
AU (1) AU2022399851A1 (fr)
CA (1) CA3241479A1 (fr)
IL (1) IL313248A (fr)
MX (1) MX2024006773A (fr)
TW (1) TW202329975A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260053743A1 (en) * 2024-08-26 2026-02-26 Incyte Corporation Topical skin formulations of a pharmaceutically acceptable salt of ruxolitinib
CN119424386B (zh) * 2024-10-12 2025-07-25 深圳市泰力生物医药有限公司 含有芦可替尼的外用速溶膜及其制备方法和应用

Also Published As

Publication number Publication date
IL313248A (en) 2024-08-01
JP2024544686A (ja) 2024-12-03
TW202329975A (zh) 2023-08-01
MX2024006773A (es) 2024-08-20
CN118714997A (zh) 2024-09-27
KR20240139048A (ko) 2024-09-20
AU2022399851A1 (en) 2024-06-20
EP4440546A1 (fr) 2024-10-09

Similar Documents

Publication Publication Date Title
AU2019213835B2 (en) Topical formulations comprising tofacitinib
US20250049817A1 (en) Jak inhibitor with a vitamin d analog for treatment of skin diseases
KR102914891B1 (ko) 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형
US12551485B2 (en) Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
CA3241479A1 (fr) Formulations topiques de ruxolitinib avec un agent d'ajustement du ph a base d'amine organique pour le traitement de maladies de la peau
WO2023102559A1 (fr) Formulations topiques de ruxolitinib avec un agent d'ajustement du ph à base d'amine organique pour le traitement de maladies de la peau
IL287130B (en) Methods for treating itching
WO2023016583A1 (fr) Composition de ruxolitinib et utilisation associée
CN117157080A (zh) 用于治疗皮肤病的含维生素d类似物的jak抑制剂
WO2007086582A1 (fr) LOTION EN ÉMULSION DE TYPE HUILE DANS L'EAU CONTENANT DE LA 22-OXA-1α,25-DIHYDROXYVITAMINE D3 ET MÉTHODE DE TRAITEMENT D'UNE MALADIE CUTANÉE UTILISANT LADITE LOTION
EP3666254A2 (fr) Composition pharmaceutique contenant un (r)-n-[1-(3,5-difluoro-4-méthanesulfonylamino-phényl)-éthyl]-3-(2-propyl-6-trifluorométhyl-pyridin-3-yl)-acrylamide
US20240226068A9 (en) Topical Formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for the Treatment of Rheumatoid Arthritis, Melanoma, Squamous Cell Carcinoma, Atopic Dermatitis, and Psoriasis
JP5674786B2 (ja) タクロリムスを含有する水中油型クリーム状組成物
CN115397398A (zh) 环状酯肽的局部药物制剂

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: COVER PAGE PUBLISHED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W160 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: COVER PAGE PUBLISHED

Effective date: 20240702

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260115